September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose positron emission tomography). This acquisition includes the license to market GE Healthcare’s SteriPET (FDG) imaging agent in Italy.

Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. 

The Minneapolis Heart Institute Foundation (MHIF) announced its first implant of the Portico Re-sheathable Transcatheter Aortic Valve System, developed by St. Jude Medical. 

September 15, 2014 — A new gene-directed drug being tested through a research study called GENETIC-AF may improve care, quality of life and survival in patients with heart failure and atrial fibrillation (AF). A previous study showed the drug being evaluated, called bucindolol hydrochloride, reduced symptomatic AF when compared with placebo in patients with a specific gene variation, or genotype. In the current study, bucindolol, a betablocker, is being compared with another betablocker called metoprolol succinate, a heart failure drug approved by the U.S. Food and Drug Administration (FDA).

September 15, 2014 — A new minimally invasive surgery involving a stent graft made from a 3-D image of the patient’s anatomy could eliminate the need for open surgery for some patients suffering from abdominal aortic aneurysms (AAA).

St. Jude Medical Inc. announced primary outcome two-year data from the FAME 2 Trial, which demonstrated sustained superiority with FFR-guided PCI using St. Jude Medical PressureWire technology in patients with stable coronary artery disease (CAD) compared to standard medical therapy alone.

Claret Medical Inc. announced that it has entered into an agreement for up to $18 million in a Series B financing. The Series B round was led by Santé Ventures, a prominent healthcare-focused venture capital firm with $260 million in capital under management, with participation from Lightstone Ventures, a leading venture capital firm with $172 million under management.

September 12, 2014 — Ecolab Healthcare announced the availability of the PD220 patient drape, the first to market specifically for Boston Scientific’s subcutaneous implantable cardioverter-defibrillator (S-ICD) procedure.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now